START Doses First Patient in Pioneering mRNA-4106 Trial
In a significant development for cancer research, the START Center for Cancer Research has successfully dosed the first patient in the United States in Moderna's Phase 1 clinical trial of mRNA-4106, a novel therapy designed to target multiple tumor antigens in patients with advanced solid tumors.
This milestone marks a crucial step in START's mission to deliver groundbreaking cancer therapies through community-based trials. Dr. Amita Patnaik, the physician responsible for administering the first dose, highlighted the importance of this trial, stating, "With mRNA-4106, we are entering a new frontier in cancer immunotherapy. Our commitment to providing patients access to innovative treatments is exemplified through this first-in-human trial. At START, our goal is to convert scientific advancements into real-world therapeutic options for patients. This study exemplifies that commitment."
Understanding mRNA-4106 and Its Promising Potential
The Phase 1 trial, with ClinicalTrials.gov identifier NCT06880549, is set to assess the safety, immune response, and preliminary efficacy of mRNA-4106, both alone and in combination with checkpoint inhibitors. This approach promises to offer a multivalent strategy to expand treatment choices for patients, moving forward from traditional single-target immunotherapies.
Nick Slack, MBE, Chairman and CEO of START, shared his enthusiasm about the trial, emphasizing the organization’s core values: "This milestone underscores our commitment to expediting the development of advanced cancer therapies by bringing them directly to patients in their own communities. Collaborating with Moderna in this innovative trial reflects our dedication to providing faster and more accessible early-phase trials that create meaningful opportunities for both patients and sponsors."
The Role of Community in Cancer Research
The innovative aspect of this trial lies not just in the mRNA technology, but also in the collaborative efforts between START and Moderna. Dr. Rose Loughlin, Executive Vice President of Research at Moderna, expressed excitement over the inclusive design of mRNA-4106, stating, "We aimed to develop a therapy that covers a wide range of antigens shared across various patients and tumor types. With the help of forward-thinking organizations like START, we are optimistic about mRNA's potential to revolutionize cancer treatment."
START is well-positioned to play a significant role in accelerating access to transformative therapies, dedicating itself to the mission of providing "Hope Through Access" to patients globally. This commitment is crucial, especially as the healthcare landscape continues to evolve.
Commitment to Clinical Excellence
The START Center for Cancer Research has a distinguished history within the community oncology framework. With a focus on early-phase clinical trials, START has facilitated access to over a thousand trials involving cutting-edge anti-cancer agents. Notably, its clinical trial sites have contributed to the success of 45 therapies that have received FDA or EMA approval.
As a leader in the field, START comprises the largest roster of early-phase Principal Investigators across its ten clinical trial sites. This expertise not only reinforces its commitment to facilitating the transition from trials to actual treatments but also provides hope and support to patients and families around the world.
About START Center for Cancer Research
The START Center for Cancer Research is at the forefront of specializing in preclinical and early-phase clinical trials aimed at advancing novel anti-cancer treatments. Aiming to expedite the process from clinical trials to available therapies, START is deeply invested in the welfare of its patients, striving to provide them with access to innovative treatment options. The organization invites individuals interested in learning more to visit their official website.
START Contacts
Lauren Panco
VP, Marketing
609-216-4920
Frequently Asked Questions
1. What is mRNA-4106?
mRNA-4106 is a novel Pan-Tumor Antigen Therapy candidate aimed at treating advanced or metastatic solid tumors through immunotherapy.
2. What is the role of START in this clinical trial?
START serves as the clinical trial site for the administration of mRNA-4106, focusing on community-based early-phase cancer research.
3. How does mRNA-4106 work?
This therapy leverages mRNA technology to target multiple tumor antigens, aiming to broaden treatment options for patients with various cancer types.
4. Who is leading the trial at START?
Dr. Amita Patnaik is leading the trial at START and was responsible for administering the first dose of mRNA-4106.
5. Why is this trial significant?
This trial represents a critical advancement in cancer therapy, highlighting the potential of mRNA technology to revolutionize the treatment landscape.
